EVERNORTH HEALTH SERVICES

Express Scripts® Pharmacy Benefit Services
Pharmacy and Therapeutics (P&T) Committee
Proceedings
July 18, 2026

New Drug Evaluations

The Committee reviewed the following new drugs:

A. **Baxfendy™ (baxdrostat tablets)** AstraZeneca
B. **Beqalzi™ (sonrotoclax tablets)** BeOne Medicines
C. **Decnupaz™ (pivekimab sunirine-pvzy intravenous infusion)** AbbVie
D. **Hepcludex® (bulevirtide-gmod subcutaneous injection)** Gilead
E. **Lumvoa™ (veligrotug-vvze intravenous infusion)** Viridian
F. **Utebzi® (tebipenem pivoxil tablets)** GlaxoSmithKline
G. **Xocova® (ensitrelvir tablets)** Shionogi
H. **Xtoro™ (finafloxacin 0.3% otic suspension)** Fonseca Biosciences

New Indications for Existing Products

The Committee reviewed the following new or changes to indications for existing products: See product inserts for specific wording.

A. **Afrezza® (insulin human inhalation powder)** MannKind – Expanded age indication for pediatric patients ≥ 6 years of age to improve glycemic control in patients with diabetes mellitus.
B. **Bizengri® (zenocutuzumab-zbco intravenous infusion)** Partner Therapeutics – New indication for the treatment of adults with advanced, unresectable or metastatic cholangiocarcinoma harboring a neuregulin 1 gene fusion with disease progression on or after prior systemic therapy.
C. **Capvaxive® (pneumococcal 21-valent conjugate vaccine intramuscular injection)** Merck – Expanded age indication for active immunization for the prevention of invasive disease caused by Streptococcus pneumoniae serotypes 3, 6A, 7F, 8, 9N, 10A, 11A, 12F, 15A, 15B, 15C, 16F, 17F, 19A, 20A, 22F, 23A, 23B, 24F, 31, 33F, and 36B in pediatric patients ≥ 2 years of age through 17 years of age who are at increased risk for pneumococcal disease.
D. **Datroway® (datopotamab deruxtecan-dlnk intravenous infusion)** Daiichi Sankyo – New indication for the treatment of unresectable or metastatic triple-negative breast cancer in adults who are not candidates for programmed death receptor-1 (PD-1)/programmed death-ligand 1 (PD-L1) inhibitor therapy.
E. **Enhertu® (fam-trastuzumab deruxtecan-nxki intravenous infusion)** Daiichi Sankyo – New indications for HER2-positive early breast cancer: 1) Enhertu followed by a taxane, trastuzumab, and pertuzumab is indicated for the neoadjuvant treatment of adults with HER2-positive (IHC 3+ or ISH+) Stage II or III breast cancer as determined by a Food and Drug Administration (FDA)-authorized test; and 2) Enhertu is indicated for the adjuvant treatment of adults with HER2-positive (IHC 3+ or ISH+) breast cancer who have residual invasive disease following neoadjuvant trastuzumab (with or without pertuzumab) and taxane-based treatment.

F. **Fasenra® (benralizumab subcutaneous injection)** AstraZeneca – New indication for the treatment of patients ≥ 12 years of age with hypereosinophilic syndrome without an identifiable non-hematologic secondary cause.
G. **Hympavzi® (marstacimab-hncq subcutaneous injection)** Pfizer – Expanded indication for the routine prophylaxis to prevent or reduce with frequency of bleeding episodes in patients with hemophilia A or hemophilia B with factor VIII or factor IX inhibitors, respectively. Also, Hympavzi received an expanded pediatric age indication for patients 6 years to < 12 years of age who have hemophilia A or B.
H. **Ibrance® (palbociclib tablets and capsules)** Pfizer – New indication for Ibrance in combination with trastuzumab, with or without Perjeta (pertuzumab IV infusion), and endocrine therapy for the maintenance treatment of adults with hormone receptor (HR)-positive, HER2-positive locally advanced or metastatic breast cancer following induction treatment.
I. **Imfinzi® (durvalumab intravenous infusion)** AstraZeneca – New indication for use in combination with Bacillus Calmette-Guerin (BCG) for the treatment of BCG-naïve, high-risk non-muscle-invasive bladder cancer in adults.
J. **Inqovi® (decitabine-cedazuridine tablets)** Taiho Oncology – New indication for use in combination with Venclexta (venetoclax tablets) for the treatment of newly diagnosed acute myeloid leukemia in adults ≥ 75 years of age, or who have comorbidities that preclude the use of intensive induction chemotherapy.
K. **Keytruda® (pembrolizumab intravenous infusion)** Merck **and Keytruda Qlex® (pembrolizumab and berahyaluronidase alfa-pmph subcutaneous injection)** Merck – New indication in combination with Welireg (belzutifan tablets) for the adjuvant treatment of renal cell carcinoma with a clear cell component in adults at intermediate-high or high risk of recurrence following nephrectomy or following nephrectomy and resection of metastatic lesions. Additionally, Keytruda and Keytruda Qlex received a new indication for use in combination with Trodelvy (sacituzumab govitecan-hziy IV infusion), for the first-line treatment of adult with unresectable locally advanced for metastatic triple-negative breast cancer whose tumors express PD-L1 combined positive score (CPS) ≥ 10 as determined by an FDA-authorized test.
L. **Linzess® (linaclotide capsules)** AbbVie – Expanded age indication for pediatric patients ≥ 2 years of age for the treatment of functional constipation.
M. **Ocrevus® (ocrelizumab intravenous infusion)** Genentech – New indication for the treatment of relapsing-remitting multiple sclerosis in pediatric patients ≥ 10 years of age who weigh ≥ 25 kg.
N. **Skyrizi® (risankizumab-rzaa subcutaneous injection)** AbbVie – Expanded age indication for the treatment of moderate to severe plaque psoriasis in adults and pediatric patients ≥ 6 years of age who are candidates for systemic therapy or phototherapy.
O. **Skyrizi® (risankizumab-rzaa subcutaneous injection)** AbbVie – Expanded age indication in active psoriatic arthritis in pediatric patients ≥ 6 years of age.
P. **Tecelra® (afamitresgene autoleucel intravenous infusion)** US World Meds – Converted its prior accelerated approval to a full approval of Tecelra for the treatment of patients with unresectable or metastatic synovial sarcoma who have received prior chemotherapy, are HLA-A*02:01P, -A*02:02P, -A*02:03P, or -A*02:06P positive and whose tumor expresses the MAGE-A4 antigen as determined by FDA-approved or cleared companion diagnostic devices. Additionally, Tecelra received an expanded age indication to include pediatric patients ≥ 12 years of age in the indication above.
Q. **Tecentriq® (atezolizumab intravenous infusion)** Genentech **and Tecentriq Hybreza™ (atezolizumab and hyaluronidase-tqjs subcutaneous injection)** Genetech – New indication

as adjuvant treatment for muscle invasive bladder cancer after cystectomy in adults who have circulating tumor DNA molecular residual disease as determined by an FDA-authorized test.

R. **Tofidence® (tocilizumab-bavi intravenous infusion)** Organon – New indication for the treatment of cytokine release syndrome in adults and pediatric patients ≥ 2 years of age with chimeric antigen receptor (CAR) T cell-induced severe or life threatening cytokine release syndrome. Also, Tofidence received an expanded age indication for the treatment of coronavirus disease 2019 (COVID-19) in hospitalized adult and pediatric patients ≥ 2 years of age who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation.

S. **Tremfya® (guselkumab subcutaneous injection)** Janssen – Expanded labeling to include inhibition of progression of structural joint damage in adults who have active psoriatic arthritis.

T. **Trodelvy® (sacituzumab govitecan-hziy intravenous infusion)** Immunomedics/Gilead – New expanded indications in adults with triple-negative breast cancer. Trodelvy is now indicated for use in the first-line setting in locally advanced or metastatic triple-negative breast cancer. Additionally, Trodelvy received another new indication is for use in combination with Keytruda (pembrolizumab IV infusion) or Keytruda Qlex (pembrolizumab and berahyaluronidase alfa-pmph SC injection) for the first-line treatment of unresectable locally advanced or metastatic triple-negative breast cancer in adults whose tumors express PD-L1 (CPS ≥ 10) as determined by an FDA-authorized test.

U. **Truqap® (capivasertib tablets)** AstraZeneca – New indication, in combination with abiraterone and prednisone, for the treatment of metastatic androgen pathway modulation-naïve or -sensitive prostate cancer (previously referred to as metastatic hormone-sensitive prostate cancer) in adults that is PTEN-deficient as detected by an FDA-authorized test.

V. **Tryngolza® (olezarsen subcutaneous injection)** Ionis – New indication to reduce triglycerides and the risk of acute pancreatitis in adults with severe hypertriglyceridemia (triglycerides greater than or equal to 500 mg/dL).

W. **Tyenne® (tocilizumab-aazg intravenous infusion)** Fresenius Kabi – Expanded age indication for the treatment of COVID-19 in hospitalized pediatric patients ≥ 2 years of age who are receiving systemic corticosteroids and require supplemental oxygen, noninvasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation.

X. **Tzield® (teplizumab-mzwv intravenous infusion)** Provention/Sanofi – New indication to delay the decline in endogenous insulin production in pediatric patients ≥ 8 years of age and ≤ 17 years of age recently diagnosed with Stage 3 type 1 diabetes. This indication is approved under accelerated approval based on evidence of reduced C-peptide decline. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s).

Y. **Uptravi® (selexipag tablets)** Actelion – New pediatric indication for Uptravi tablets for the treatment of pulmonary arterial hypertension (PAH) [World Health Organization Group 1] in pediatric patients ≥ 2 years of age. Uptravi reduces N-terminal pro-B-type natriuretic peptide and is expected to delay disease progression and reduce the risk of hospitalization for PAH.

Z. **Vyvgart® (efgartigimod alfa-fcab intravenous injection)** Argenx **and Vyvgart Hytrulo® (efgartigimod alfa and hyaluronidase-qvfc subcutaneous injection)** Argenx – New indication for patients ≥ 18 years of age for the treatment of generalized myasthenia gravis. Of note, this includes all types of adults who have generalized myasthenia gravis (e.g., those who are anti-acetylcholine receptor [AChR] antibody-negative, anti-muscle-specific tyrosine kinase [MuSK] antibody-positive, anti-antibody-positive low density lipoprotein receptor-related protein

4 [LRP4], and triple seronegative [with no detectable autoantibodies against AChR, MuSK, or LRP4]).

AA. Welireg® (belzutifan tablets) Merck – New indication, in combination with Keytruda (pembrolizumab IV infusion) or Keytruda Qlex (pembrolizumab and berahyaluronidase alfa-pmph SC injection), for the adjuvant treatment of clear cell renal cell carcinoma in adults at intermediate-high or high risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions.

BB. Xeomin® (incobotulinumtoxin A injection) Merz – Expanded label and removal of exclusion for use for the treatment of upper limb spasticity in pediatric patients 2 years of age and older to not exclude spasticity caused by cerebral palsy. The updated indication is for the treatment or improvement of upper limb spasticity in patients 2 years of age and older.

CC. Zegalogue® (dasiglucagon subcutaneous injection) Zealand – Expanded indication for the treatment of severe hypoglycemia in pediatric patients with diabetes who weigh at least 20 kg.

DD. Zoryve (roflumilast cream 0.3%) Arcutis – Expanded age indication for the treatment of pediatric patients ≥ 2 years to 5 years of age with plaque psoriasis.

New Clinical Line Extensions

The Committee reviewed the following new clinical line extensions:

A. Aprepitant Injectable Emulsion (Azurity)
B. Cavhanza™ (nilotinib orally disintegrating tablets) Flex Pharma
C. Duloxetine Delayed-Release Capsules (Almatica)
D. Navitrux™ (fosaprepitant intravenous injection) Avyxa
E. Tiocystin® (tiopronin tablets) Casper Pharma
F. Trimbow® (beclomethasone dipropionate, formoterol fumarate, glycopyrrolate oral inhalation aerosol) Chiesi

New Biosimilars

The Committee reviewed the following new biosimilars:

A. Ennumo™ (pegfilgrastim-pccg subcutaneous injection) Accord Biopharma
B. Immgolis™ (golimumab-sldi subcutaneous injection) Accord BioPharma
C. Immgolis Intri™ (golimumab-sldi intravenous infusion) Accord BioPharma
D. Ranluspec® (ranibizumab-hkdz intravitreal injection) Lupin